Myriad Genetics (MYGN) Liabilities from Discontinued Operations (2019 - 2024)
Myriad Genetics (MYGN) posted quarterly Liabilities from Discontinued Operations of 4000000.0 for Q2 2024, down 67.21% quarter-over-quarter from 12200000.0 in Q2 2021.
Myriad Genetics (MYGN) Liabilities from Discontinued Operations (2019 - 2024) Analysis & Trends
Myriad Genetics (MYGN) has reported Liabilities from Discontinued Operations for 3 consecutive years, with 4000000.0 the latest figure, recorded in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.44 Bn | 209.37 Bn | 8.34 Bn |
| 2 | Danaher | 139.95 Bn | 135.60 Bn | 3.61 Bn |
| 3 | Idexx Laboratories | 46.16 Bn | 45.96 Bn | 779.09 Mn |
| 4 | Agilent Technologies | 39.67 Bn | 37.87 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 39.29 Bn | 37.21 Bn | 1.44 Bn |
| 6 | Natera | 38.61 Bn | 37.51 Bn | 696.04 Mn |
| 7 | Illumina | 29.99 Bn | 28.82 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.57 Bn | 28.51 Bn | 650.22 Mn |
| 9 | Quest Diagnostics | 26.17 Bn | 25.55 Bn | 1.03 Bn |
| 10 | Myriad Genetics | 296.09 Mn | 171.69 Mn | 137.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Jun 30, 2021 | 12.20 Mn |
| Jun 30, 2021 | 12.20 Mn |
| Dec 31, 2019 | 10.50 Mn |
| Dec 31, 2019 | 10.50 Mn |